Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

ZWI Therapeutics

Request full access

ZWI Therapeutics is a biotech startup in its early stages, focused on developing protein therapeutics with an innovative polymer

Watertown, United StatesFounded 2020Biotech & Life Sciences

About ZWI Therapeutics

ZWI Therapeutics, a biotechnology firm established in 2020, is focused on advancing protein therapeutics through the application of its proprietary polymer technology. The company was co-founded by Dr. Bob Langer and Dr. Shaoyi Jiang, who currently serves as the Robert Langer '70 Family and Friends Professor at Cornell University and is a board member. The firm is headquartered in Watertown, Massachusetts, and also has operations in Waltham, MA.

The core of ZWI's strategy revolves around its patented polycarboxybetaine polymer. This technology is engineered to create protein-polymer conjugates that demonstrate superior safety and efficacy compared to existing therapeutics that use polyethylene glycol (PEG). Preclinical studies in animal models have shown that ZWI's polycarboxybetaine conjugates exhibit low to no immunogenicity and favorable pharmacokinetics when contrasted with their PEG counterparts, suggesting potential for enhanced clinical durability and safety. This polymer platform has broad applicability, extending to the development of nanoparticles and hydrogels, particularly for cellular therapies.

The company's business model includes developing its own pipeline of drug candidates while also out-licensing its technology to other pharmaceutical companies for specific development programs. Its lead program, ZWI-001, is a uricase-polycarboxybetaine conjugate being developed for the treatment of hyperuricemia in patients with severe gout, a market with significant unmet medical needs. This program has achieved preclinical proof of concept, and following a productive INTERACT meeting with the FDA, the company is advancing toward an Investigational New Drug (IND) filing.

In January 2024, ZWI Therapeutics successfully closed a $10 million Series A financing round with investors Co-win Ventures and Sherpa Healthcare Partners. Concurrently, the company strengthened its leadership by appointing Dr. Ed Mascioli as Chief Executive Officer and adding seasoned biopharmaceutical executives Dr. Larry Miller and Dr. Ron Cohen to its Board of Directors.

Source: Dealroom company data

At a glance

Status
Operational
Employees
7
Open positions
None listed
Dealroom signal
55.1/100
Industry
Health
Sub-industry
BioTechnology
Sector
Biotechnology, Spinout, Polymers, Biotech and Pharma, proteomics, DT and LS, science-based
Business model
Manufacturing
Client focus
B2B
Links
Website

Funding history

3 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
SERIES AOther financing Jan 2024 — — Undisclosed ↗
SERIES AOther financing Mar 2021 $10M $40M Cowin Venture —
Showing the latest 2 of 3 recorded eventsBook a demo for the full funding history →

Growth signals

ZWI Therapeutics website traffic

Latest recorded traffic for ZWI Therapeutics is 300 monthly website visits, up 7.1% over the last three months. ZWI Therapeutics's team grew 0% over the past year.

Latest monthly visits300 3-month web change+7.1% 1-year team growth0%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

ZWI Therapeutics in the Watertown ecosystem

Live from Dealroom

The ZWI Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

2 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A1 investor entered at this stage

  • Cowin Venture

Other known investors1 additional known investor

  • University of Washington
Team profiled 1 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 1 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
🇺🇸 United States · Watertown HQ
Book a demo for the full country breakdown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about ZWI Therapeutics on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See ZWI Therapeutics’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.